Our Focus on Immuno-Oncology

In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.

The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.

READ MORE

NEWS RELEASE

Devonian Reports Positive Results in MASH Liver Study

In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.   Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…

READ MORE

EVENT

Exhibition Announcement: SMC Laboratories to Exhibit at the 61st Annual Meeting of the Japan Society of Hepatology

SMC Laboratories, Inc. is pleased to announce our participation in the 61st Annual Meeting of the Japan Society of Hepatology, to be held on June 5–6, 2025, at Hotel New Otani, Tokyo.   We will once again be showcasing our preclinical models, including the STAM™ mouse for MASH and MASH-HCC, along with other inflammation- and…

READ MORE

Front. Immunol.

"Chitinase-1 inhibition attenuates metabolic dysregulation and restores homeostasis in MASH animal models" (Front. Immunol., DOI: 10.3389/fimmu.2025.1544973, 2025)

READ MORE

STAM™ Model | MASH & Fibrosis & HCC

Our STAM™ model is a model that recapitulates the same disease progression as human MASH/HCC.

READ MORE

SERVICE

Search by topics

Our Patented original technologySTAM™ mouse

We are contributing to the world through providing cutting-edge non-clinical pharmacology studies with our unique patented technology, the STAM™ mouse. In order to develop a new drug, it is important to be able to accurately measure the effectiveness of the drug at the non-clinical trial stage. The STAM™ mouse, a model that more accurately reflects human pathology, plays a major role for this purpose.

LEARN MORE

MODEL LINEUP

Introducing disease mice models related to inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity, including the STAM™ mouse, the world's first MASH model mouse developed in our company.

STAM™ Model | MASH & Fibrosis & HCC

DISEASE AREAMASH/NASH-HCCTHERAPEUTIC AREAS

LEARN MORE

Bleomycin-induced pulmonary fibrosis model

DISEASE AREAIPFTHERAPEUTIC AREAS

LEARN MORE

Porcine Pancreatic Elastase (PPE) model

COPDDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

CCl4-induced liver fibrosis model

CirrhosisDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

BDL model (Bile duct ligation)

DISEASE AREAPBCTHERAPEUTIC AREAS

LEARN MORE

TAA-induced acute liver failure model

ALFDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

VIEW MORE

New stage

Our service and disease mouse models bridge the development of the next- Generation Cancer Therapies in the field of Immuno-oncology.

LEARN MORE

New stage

SMC Laboratories,Inc.

COMPANY

At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs.

LEARN MORE

PUBLICATION

We, SMC Laboratories, are highly regarded worldwide as a consulting – based CRO that designs tailored to the needs of pharmaceutical companies and research institutions.

NEWS

2025.08.15

Latest Advances in MASH Therapy: Resmetirom and Semaglutide, Evaluation in the STAM Model

The FDA approved two therapies for MASH: the oral agent Resmetirom in 2024 and the GLP-1 receptor agonist Semaglutide on August 15, 2025 (FDA announcement). Resmetirom reduces liver fat, while Semaglutide improves metabolism and slows disease progression, demonstrating distinct mechanisms of action. These approvals represent a significant and welcome step forward in MASH treatment, and…

READ MORE

2025.08.05

PRODUCTS AND SERVICE UPDATE

Clear Negative Correlation Between FVC and Ashcroft Score in Bleomycin-Induced Lung Fibrosis Model

In preclinical drug development for fibrotic lung diseases, the ability to quantitatively and reproducibly assess disease severity is essential. At SMC Laboratories, we evaluated the relationship between lung function and histopathological fibrosis in the bleomycin-induced lung fibrosis mouse model. Specifically, we analyzed the correlation between forced vital capacity (FVC) and the Ashcroft histological fibrosis score….

READ MORE

2025.07.25

PRODUCTS AND SERVICE

New Model Launch: Introduction of the Rat CCl₄-Induced Acute Liver Injury Model

SMC Laboratories is pleased to announce the launch of a new in vivo platform: the rat CCl₄ (carbon tetrachloride)-induced acute liver injury model. This model reproduces acute hepatocellular injury and is well-suited for the non-clinical evaluation of compounds with hepatoprotective or anti-inflammatory properties. Following a single intraperitoneal administration of CCl₄, serum ALT and AST levels…

READ MORE

2025.07.12

PRODUCTS AND SERVICE

Launch of Rat Disease Model Services

To better meet evolving research needs, SMC Laboratories has officially launched a lineup of preclinical rat disease models across multiple therapeutic areas. ■ Background of Rat Model Introduction We have observed a significant rise in inquiries for rat-based studies due to the following reasons: Larger body size of rats allows for increased sample volume per…

READ MORE

2025.06.07

Column

Chitinase-1 Inhibition Attenuates MASH Progression: A Novel Therapeutic Approach via Metabolic Reprogramming

In May 2025, a collaborative research team from OncoArendi Therapeutics and academic institutions in Poland published a study in Frontiers in Immunology highlighting the therapeutic potential of the CHIT1 inhibitor OATD-01. Using multiple MASH (metabolic dysfunction-associated steatohepatitis) models, including the STAM™ mouse, the study demonstrated that OATD-01 can modulate macrophage metabolism and suppress disease progression….

READ MORE

2025.06.06

Column

A Preclinical Package to Maximize the Value of Your MASH Candidate

MASH

  Featured in Frontiers in Immunology: A Preclinical Package to Maximize the Value of Your MASH Candidate We are excited to share that a study for which we conducted the preclinical efficacy pharmacology has been published in the journal, Frontiers in Immunology. The paper features the novel MASH drug candidate, “OATD-01,” from our client, Molecure…

READ MORE

VIEW MORE